Corticosteroid Medications Compared

Prednisone is the most commonly prescribed oral corticosteroid in the United States, used across an enormous range of conditions including allergic reactions, asthma exacerbations, autoimmune diseases (rheumatoid arthritis, lupus, inflammatory bowel disease), and organ transplant rejection prevention. It is a prodrug — pharmacologically inactive until converted to prednisolone by 11β-hydroxysteroid dehydrogenase in the liver. In patients with normal hepatic function, this conversion is efficient and clinically seamless.

Prednisone has a plasma half-life of 3–4 hours, but its biological effect on tissues lasts 18–36 hours, allowing once-daily dosing for most indications. Its mineralocorticoid activity is low relative to hydrocortisone but not absent, so sodium retention and potassium loss can occur, particularly at higher strengths or with prolonged use. Rayos is a delayed-release formulation designed to be taken at bedtime; it releases drug early in the morning to target the inflammatory cytokine surge that peaks around 4–6 AM, which is relevant in rheumatoid arthritis morning stiffness.

Prednisolone is the active form of prednisone — the compound that prednisone is converted to in the liver. Because it does not require hepatic activation, prednisolone is preferred in patients with significant liver disease or impairment, where prednisone conversion may be unreliable. It is also the preferred agent in pediatric patients: oral solution formulations (5mg/5mL and 15mg/5mL) allow weight-based administration in children who cannot swallow tablets, and prednisolone is the agent used in protocols such as the MAST trial for childhood asthma exacerbations.

In clinical practice, prednisone and prednisolone are considered therapeutically equivalent in patients with normal liver function and are interchangeable at the same numerical strength. Prednisolone is widely available as an oral liquid, making it practically useful in any patient with dysphagia or who requires a liquid formulation. Potency and side effect profile are identical to prednisone.

Methylprednisolone offers slightly greater anti-inflammatory potency than prednisone (5× vs. 4× hydrocortisone equivalence) and has the advantage of virtually no mineralocorticoid activity, making it less likely to cause sodium retention and fluid overload. The oral form (Medrol) is available in a convenient dose pack — a 4mg tablet blister card with a built-in tapering schedule — frequently prescribed for short courses of treatment in conditions such as acute allergic reactions, contact dermatitis, or acute musculoskeletal inflammation. This pre-packaged taper removes ambiguity about how to reduce the dose over time.

Solu-Medrol is the intravenous form, used in acute settings including severe asthma exacerbations, multiple sclerosis relapses (high-dose pulse therapy), spinal cord injury, and solid organ transplantation. The IV preparation acts quickly and allows precise delivery when oral medications are not feasible. Methylprednisolone's combination of higher potency, minimal mineralocorticoid activity, and availability in both oral and IV forms makes it one of the most versatile corticosteroids in acute hospital care.

Dexamethasone is the most potent systemic corticosteroid in widespread clinical use, with 25 times the anti-inflammatory potency of hydrocortisone at equipotent amounts. It is uniquely distinguished by two pharmacological features: its exceptional potency and its complete lack of mineralocorticoid activity. These properties make it the preferred agent in situations where maximal anti-inflammatory effect with minimal fluid retention is needed — cerebral edema (reducing brain swelling around tumors or after surgery), severe croup in children, cancer treatment-related nausea (as an anti-emetic), and COVID-19 in patients requiring supplemental oxygen or mechanical ventilation (based on the landmark RECOVERY trial).

Dexamethasone also has the longest biological half-life among the common systemic corticosteroids — 36–72 hours — meaning a single administration suppresses the HPA axis for more than a day. This is an important consideration when using it even briefly: HPA suppression can occur with as few as 1–2 doses at higher amounts, and repeated or prolonged use requires careful tapering. Dexamethasone is available in an unusually wide range of tablet strengths, as an elixir, and as injectable forms. It crosses the blood-brain barrier readily, which underlies its use in neurological conditions.

Hydrocortisone is the synthetic form of cortisol — the primary glucocorticoid produced by the human adrenal cortex — and serves as the reference standard against which all other corticosteroids are measured. Because it most closely mimics the body's natural hormone, it is the drug of choice for adrenal insufficiency replacement therapy (primary adrenal insufficiency / Addison's disease and secondary adrenal insufficiency), where the goal is to replicate the normal cortisol production pattern. This physiologic use requires careful timing and attention to sick-day rules — patients on replacement hydrocortisone must increase their dose during illness, injury, or surgery to prevent adrenal crisis.

Hydrocortisone's significant mineralocorticoid activity (relative to other synthetic corticosteroids) makes it suitable for adrenal replacement — patients with primary adrenal insufficiency need both glucocorticoid and mineralocorticoid replacement, and hydrocortisone provides some of both. However, this same mineralocorticoid activity makes it less ideal than prednisone or methylprednisolone for anti-inflammatory use, as sodium retention and potassium loss are more pronounced. Solu-Cortef is the intravenous form used in adrenal crisis and high-stress perioperative situations.

Oral budesonide occupies a unique position in the corticosteroid landscape: it is taken by mouth and acts primarily on the lining of the intestinal tract rather than entering systemic circulation in meaningful amounts. Entocort EC (budesonide 3mg extended-release capsules) is formulated to release drug in the terminal ileum and right colon, targeting the most commonly affected areas in Crohn's disease. Uceris (budesonide 9mg multi-matrix tablets) uses a different release mechanism designed to deliver drug throughout the colon for ulcerative colitis induction.

The key pharmacological feature of oral budesonide is its high first-pass hepatic metabolism — approximately 90% of absorbed drug is inactivated on first pass through the liver, leaving only about 10% reaching systemic circulation. This dramatically limits systemic corticosteroid exposure compared to prednisone, reducing (though not eliminating) the risks of HPA axis suppression, hyperglycemia, and immunosuppression. For mild-to-moderate IBD affecting the relevant bowel segments, budesonide is preferred over prednisone precisely because of this systemic safety advantage. It is not appropriate for severe disease or extraintestinal complications, where systemic steroids remain necessary.

Fluticasone propionate (Flovent) has historically been the most prescribed inhaled corticosteroid in the United States and is available in two delivery systems: the HFA metered-dose inhaler (pMDI) and the Diskus dry powder inhaler (DPI). The two devices differ in particle size, inspiratory flow requirements, and technique — the Diskus requires a rapid, deep inhalation, while the HFA can be used with a spacer and is suitable for a wider range of patients including young children. Flovent HFA was discontinued by GSK in early 2024, though authorized generics have become available.

Fluticasone propionate undergoes extensive first-pass metabolism in the liver, and its systemic bioavailability from the swallowed fraction is very low (~1%), significantly limiting systemic side effects compared to oral steroids. It is approved for asthma maintenance in patients 4 years and older (HFA) and 4 years and older (Diskus). As the ICS component of Advair (with salmeterol), it is one of the most studied inhaled corticosteroids for both asthma and COPD.

Budesonide is available in two inhaled formulations: the Pulmicort Flexhaler (dry powder inhaler for older children and adults) and Pulmicort Respules (nebulizer suspension for young children from 12 months to 8 years). The Respules formulation is particularly important because it provides an ICS option for toddlers and infants who cannot use a DPI or coordinate pMDI use even with a mask-and-spacer. Budesonide inhaled is the preferred ICS during pregnancy due to the most extensive safety data in this population.

Inhaled budesonide has moderate systemic bioavailability from the lung-absorbed fraction (~25–40%), though the swallowed fraction is extensively metabolized by the liver (~10% bioavailability), resulting in overall systemic exposure substantially lower than an equivalent oral prednisone dose. It is also the ICS component of Symbicort (with formoterol), one of the most prescribed combination products for both asthma and COPD.

Ciclesonide (Alvesco) is a prodrug that is inhaled in an inactive form and then cleaved by esterases in the lung tissue into its active metabolite, desisobutyryl-ciclesonide. This lung-targeted activation means that drug deposited in the oropharynx — before reaching the lungs — remains largely inactive, substantially reducing the risk of oropharyngeal side effects such as oral candidiasis (thrush) and dysphonia that affect other ICS. This property can be an advantage for patients who have experienced thrush with other ICS despite adequate mouth rinsing.